Diagnostic and prognostic impact of osteopontin expression in endometrial cancer

Han Byoul Cho, Eun Suk Kang, YoungTae Kim, Jae-Hoon Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The role of osteopontin as a biomarker in endometrial cancer has not been conclusively established. We evaluated the expression and potential of osteopontin as a biomarker for endometrial cancer. Real-time polymerase chain reaction and immunohistochemistry revealed osteopontin overexpression in endometrial cancer. The plasma osteopontin level in endometrial cancer was significantly higher than in healthy controls (P < 0.001). In FIGO stage I endometrial cancer, osteopontin correctly identified 18 of 29 cases (62.1%) that were not detected by CA125. By Cox multivariate analysis, osteopontin positivity was an independent prognostic factor for disease-free survival (hazard ratio = 3.18, P= 0.035).

Original languageEnglish
Pages (from-to)313-323
Number of pages11
JournalCancer Investigation
Volume27
Issue number3
DOIs
Publication statusPublished - 2009 Mar 1

Fingerprint

Osteopontin
Endometrial Neoplasms
Biomarkers
Disease-Free Survival
Real-Time Polymerase Chain Reaction
Multivariate Analysis
Immunohistochemistry

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{c84eb71ebb4744bdaf30267102407b85,
title = "Diagnostic and prognostic impact of osteopontin expression in endometrial cancer",
abstract = "The role of osteopontin as a biomarker in endometrial cancer has not been conclusively established. We evaluated the expression and potential of osteopontin as a biomarker for endometrial cancer. Real-time polymerase chain reaction and immunohistochemistry revealed osteopontin overexpression in endometrial cancer. The plasma osteopontin level in endometrial cancer was significantly higher than in healthy controls (P < 0.001). In FIGO stage I endometrial cancer, osteopontin correctly identified 18 of 29 cases (62.1{\%}) that were not detected by CA125. By Cox multivariate analysis, osteopontin positivity was an independent prognostic factor for disease-free survival (hazard ratio = 3.18, P= 0.035).",
author = "Cho, {Han Byoul} and Kang, {Eun Suk} and YoungTae Kim and Jae-Hoon Kim",
year = "2009",
month = "3",
day = "1",
doi = "10.1080/07357900802375738",
language = "English",
volume = "27",
pages = "313--323",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "3",

}

Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. / Cho, Han Byoul; Kang, Eun Suk; Kim, YoungTae; Kim, Jae-Hoon.

In: Cancer Investigation, Vol. 27, No. 3, 01.03.2009, p. 313-323.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Diagnostic and prognostic impact of osteopontin expression in endometrial cancer

AU - Cho, Han Byoul

AU - Kang, Eun Suk

AU - Kim, YoungTae

AU - Kim, Jae-Hoon

PY - 2009/3/1

Y1 - 2009/3/1

N2 - The role of osteopontin as a biomarker in endometrial cancer has not been conclusively established. We evaluated the expression and potential of osteopontin as a biomarker for endometrial cancer. Real-time polymerase chain reaction and immunohistochemistry revealed osteopontin overexpression in endometrial cancer. The plasma osteopontin level in endometrial cancer was significantly higher than in healthy controls (P < 0.001). In FIGO stage I endometrial cancer, osteopontin correctly identified 18 of 29 cases (62.1%) that were not detected by CA125. By Cox multivariate analysis, osteopontin positivity was an independent prognostic factor for disease-free survival (hazard ratio = 3.18, P= 0.035).

AB - The role of osteopontin as a biomarker in endometrial cancer has not been conclusively established. We evaluated the expression and potential of osteopontin as a biomarker for endometrial cancer. Real-time polymerase chain reaction and immunohistochemistry revealed osteopontin overexpression in endometrial cancer. The plasma osteopontin level in endometrial cancer was significantly higher than in healthy controls (P < 0.001). In FIGO stage I endometrial cancer, osteopontin correctly identified 18 of 29 cases (62.1%) that were not detected by CA125. By Cox multivariate analysis, osteopontin positivity was an independent prognostic factor for disease-free survival (hazard ratio = 3.18, P= 0.035).

UR - http://www.scopus.com/inward/record.url?scp=63349090034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63349090034&partnerID=8YFLogxK

U2 - 10.1080/07357900802375738

DO - 10.1080/07357900802375738

M3 - Article

VL - 27

SP - 313

EP - 323

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 3

ER -